All In Biotech

Drug Trial Radar · NCT05555251

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

18

Actual

Start

Jul 28, 2022

Primary completion

Feb 7, 2024

Study completion Feb 7, 2024

Sponsor

Lead sponsor
BioInvent International ABIndustry
Sponsor type
Industry
First posted
Sep 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy. However, many patients remain uncured and develop resistance to trastuzumab resulting in relapse or progression of the disease. BI-1607, a human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targets CD32b (Fc Gamma Receptor IIB), it is intended to enhance the efficacy and overcome resistance to existing cancer treatments such as trastuzumab. This is a Phase 1/2a, first-in-human, open-label, multicenter, dose-escalation, consecutive-cohort study of BI-1607 in combination with trastuzumab in subjects with HER2+ advanced solid tumors whose tumor has progressed after standard therapy.

Conditions

  • HER2-positive Breast Cancer
  • HER2-positive Gastric Cancer
  • HER2-positive Metastatic Breast Cancer
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Gastric Adenocarcinoma

Interventions

  • BI-1607Drug

    administered at different doses in Phase I by intravenous infusions every 3 weeks.

  • BI-1607Drug

    administered at the recommended dose in Phase 2a by intravenous infusions every 3 weeks.

  • TrastuzumabDrug

    administered at 8mg/kg for the first infusion and at 6mg/kg in subsequent infusions by intravenous infusions every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the safety and tolerability profile of BI-1607 in combination with trastuzumabTime frame: End of treatment visit or 30 days after last dose of study drug.
  2. Identify Dose limiting toxicities, determine the maximum tolerate dose of BI-1607 and propose a recommended Phase 2 dose (RP2D) for evaluation of BI-1607 in combination with trastuzumab.Time frame: 22 days

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • Evang. Kliniken Essen-Mitte

    Essen, Germany

  • Krankenhaus Nordwest

    Frankfurt, Germany

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Complejo hospitalario Ruber Juan Bravo

    Madrid, Spain

  • Churchill Hospital

    Oxford, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.